Physician profile
George Hall
NPI 1639171143
$31,398.79
in general payments reported to CMS, 2019-2025
78 companies · $4,607 in 2025
The $4,607 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,788 · 2020: $2,767 · 2021: $4,288 · 2022: $4,976 · 2023: $4,305 · 2024: $4,668 · 2025: $4,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $81.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,498.60 |
| Education | $81.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,700.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $3,163.08 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $1,871.66 | 2019-2025 | Repatha, Evenity, Repatha |
| Novo Nordisk INC | $1,548.18 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $1,542.34 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Gilead Sciences, INC. | $1,418.37 | 2019-2025 | |
| Esperion Therapeutics, INC. | $1,393.29 | 2021-2025 | Nexletol, Nexlizet |
| Pfizer INC. | $1,296.79 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,280.24 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Abbvie INC. | $1,275.38 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,005.17 | 2019-2025 | Jardiance, Cyltezo, Jascayd |
| Janssen Pharmaceuticals, INC | $941.77 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $895.74 | 2019-2024 | |
| Amarin Pharma, INC. | $785.38 | 2019-2023 | |
| Exact Sciences Corporation | $738.10 | 2023-2025 | Cologuard Collection Kit |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.